Home | Products | Oligo Technology | Fluorescent Probes | Modifications | Oligo Design Tools | Online Order
e-oligos DNA Synthesis
DNA Synthesis
Beta-Cyanoethyl Phosphoramidite Chemistry
The synthesis of DNA from ί-cyanoethyl phosphoramidite monomers is currently the industry standard. With this method, high coupling efficiencies are easily attained. The absence of side reactions also confers high biological activity of the synthetic oligonucleotide. In the basic reaction cycle, a solid support, derivatized with the initial protected nucleoside, is contained in a reaction column. Reagents and solvents are pumped through the column to effect the addition of successive protected nucleotide monomers (phosphoramidites). Each addition cycle includes detritylation, activation, coupling, oxidation, and capping. Intervening wash steps remove excess reactants and by-products of reaction. After the chain elongation is complete, the oligomer must be removed from the support and fully deprotected. The crude product can be purified on an Oligo-Pak purification column, by gel electrophoresis, or by HPLC.

Solid Support
The synthesis of an oligomer begins with the selection of the reaction column containing the initial support-bound protected nucleoside. The reactive 5’-hydroxyl group of the support-bound nucleoside is protected with a dimethoxytrityl (DMT) group. The 3’-hydroxyl group of the nucleoside is covalently attached, through an appropriate hydrocarbon spacer, to the Controlled Pore Glass (CPG) support. 500A CPG is recommended for oligomers up to 50 bases in length; 1000A CPG is recommended for oligomers more than 50 bases in length. Following this guideline provides better coupling efficiency by minimizing steric hindrance.

The exocyclic amines of 2’-deoxyadenosine (dA), 2’-deoxycytidine (dC) and 2’ deoxyguanosine (dG) have to be protected during synthesis to prevent side reactions from taking place at these sites. The dC and dA monomers are protected by benzoyl (bz) groups at the N4 and N6 positions, respectively, while the dG is protected at the N2 position by an isobutyryl (ibu) group. These groups are removed after synthesis of the oligomer is complete, during deprotection. The phosphoramidite monomers are also protected at the the 5’-hydroxyl position with a DMT group, while the 3’-phosphite is modified by ί-cyanoethyl and diisopropylamine groups.

In the first step of the synthesis cycle, the acid labile DMT group of the support-bound monomer is removed with a dichloroacetic acid solution (DCA). The resulting cation is orange. The yield of the DMT cation can be estimated spectrophotometrically and be used to determine step-wise coupling efficiency. As the DNA bases are acid-labile, the detritylation step must only be as long as is necessary to ensure complete detritylation.

After detritylation the next protected phosphoramidite is delivered to the reaction column. Tetrazole is used to activate the phosphoramidite. The two reagents are mixed just prior to delivery to the reaction column. Tetrazole, a weak acid, protonates the tertiary nitrogen group of the phosphoramidite so that the diisopropylamine moiety becomes a good leaving group.
The Coupling Mechanism is a nucleophylic attack by the free 5’-hydroxyl group on the 3’-phosphorous of the incoming activated monomer. For this reason, it is important to have a totally hydroxyl-free environment in the column. To ensure this, dry acetonitrile is used as the general solvent, and all the reagents and solvents are maintained in the anhydrous state. Under these conditions the coupling efficiencies are very high, thereby permitting synthesis of long oligomers.

The most recently added monomer is now linked to the chain by trivalent phosphite bond. However, phosphorus linkages are more stable when the oxidation state is pentavalent, as is the case in native DNA. Therefore, the bond is oxidized in an iodine solution.

Since 1-2% of the free 5’-hydroxyl groups do not undergo reaction, unreacted chains (failure sequences) must be capped to prevent further elongation in the the next cycles. For this step, acidic anhydride and N-methylimidazole are mixed to form an activated acetylating agent.

Following the capping step, the cycle of reactions is repeated, beginning with the detritylation step, until the chain elongation is complete.

Final Detritylation
If the oligomer is to be purified by Oligo-Pak column methods or by Reverse Phase HPLC, the DMT group is left on the 5’-OH of the oligomer and is removed only after purification. If the oligomer is to be purified by gel electrophoresis or ion exchange HPLC, the oligonucleotide is detritylated at this stage.

Removal from Support and Deprotection
After the specified sequence has been assembled, the oligomer must be removed (cleaved) from the support and fully deprotected prior to use.
A 90 minute room temperature treatment with ammonium hydroxide is used to cleave the oligomer from the support and to deprotect the phosphorus by ί-elimination of the cyanoethyl group. A 24 hour room temperature treatment or an 8 hour 55’C treatment with ammonium hydroxide effectively removes the capping groups and the benzoyl and isobutyryl groups protecting the exocyclic amines.
After cleavage/deprotection, the resulting crude mixture contains the tritylated product oligomer, the truncated failure sequences with free 5’-hydroxyl ends, by-products of deprotection (benzamide, isobutyramide, acrylonitrile, and acetamide), and silicates from hydrolysis of the glass support.

The crude oligonucleotide can be purified using reverse phase chromatography or by gel electrophoresis. Reverse phase chromatography using manual cartridges or HPLC depend on the hydrophobic trityl group to separate the product from the failure sequences. Reverse phase purification is not recommended for oligos longer than 40mer as single strand oligos themselves are hydrophobic. All Gene Link oligos shorter than 40mer usually does not require any further purification if the application is for PCR or sequencing. Gel purification is strongly advised for all applications involving cloning of the product, example mutagenesis, cloning or gene construction application.

Agrawal, S. (1993). Protocols for Oligonucleotides and Analogs, 20. Agrawal S. (1994). Protocols for Oligonucleotide Conjugates, 26. Beaucage, S. L. and Caruthers, M. H. (1981). Tetrahedron Lett., 22, 1859. Eckstein, F. (1991). Oligonucleotides and Analogies. Letsinger, R. L. finnan, J. L., Heavner, G. A., and Lunsford, W. B. (1975). J. Am. Chem. Soc., 97, 3278. McBride, L. J. and Caruthers, M. H. (1983). Tetrahedron Lett., 24, 245. Matteucci, M. D. and Caruthers, M. H. (1980). Tetrahedron Lett. 21, 719.

Enter the letters you see above for verification:

Order Status | Customer Service | Site Map | Request Literature | About e-oligos | Contact Us |   Search
July 28, 2017 e-oligos(tm) is a brand of Gene Link. e-oligos(tm) and the binary helix(tm) All graphic art is a trade mark of Gene Link, Inc. Copyright 2017
    Terms and Conditions    Licenses    Privacy Policy